Potential benefit of inhibitors of advanced glycation end products in the progression of type II diabetes: A study with aminoguanidine in C57/BLKsJ diabetic mice
- 1 December 1998
- journal article
- research article
- Published by Elsevier in Metabolism
- Vol. 47 (12) , 1477-1480
- https://doi.org/10.1016/s0026-0495(98)90073-7
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Glycation-dependent, reactive oxygen species-mediated suppression of the insulin gene promoter activity in HIT cells.Journal of Clinical Investigation, 1997
- Long Term Effects of Aminoguanidine on Insulin Release and Biosynthesis: Evidence That the Formation of Advanced Glycosylation End Products Inhibits B Cell FunctionEndocrinology, 1997
- Glycation of insulin in the islets of Langerhans of normal and diabetic animalsDiabetes, 1996
- Glycation and Diabetic ComplicationsDiabetes, 1994
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1993
- Preservation of insulin mRNA levels and insulin secretion in HIT cells by avoidance of chronic exposure to high glucose concentrations.Journal of Clinical Investigation, 1992
- Effects of high glucose on insulin secretion by isolated rat islets and purified beta-cells and possible role of glycosylationDiabetes, 1989
- Advanced Glycosylation End Products in Tissue and the Biochemical Basis of Diabetic ComplicationsNew England Journal of Medicine, 1988
- DEVELOPMENT OF THE INSULIN SECRETORY DEFECT IN GENETICALLY DIABETIC (db/db) MOUSEActa Endocrinologica, 1978
- Diabetes, a New Mutation in the MouseScience, 1966